NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,783.49 mln
Float69.56 mln
Earnings Date08/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-1.68
Likely manipulated
1-Year Forecast
40.45
Strong upside
Relative Strength
82
/ 100
Strongly outperforming
Debt / Equity
0.08
Debt-free
ROE
-44.70
Deeply negative
Business Description
Tango Therapeutics is a Boston-based drug discovery company focused on developing targeted cancer treatments for patients with limited options. Its lead programs include two PRMT5 inhibitors currently in clinical trials for pancreatic, lung, and brain cancers, as well as a separate therapy designed to help the immune system recognize and attack lung tumors driven by a specific genetic mutation. Founded in 2017, the company builds its pipeline around matching treatments to the precise genetic profiles of cancer patients.
